🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOther Peptides & Research CompoundsBPC-157 actually fixed my bad knee?? Is this placebo — looking for input

BPC-157 actually fixed my bad knee?? Is this placebo — looking for input

Dr.BariatricHTX Fri, May 16, 2025 at 4:21 AM 10 replies 1,406 viewsPage 1 of 2
This thread is more than 12 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
May 16, 2025 at 4:21 AM#1

My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my material.

A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

The narrow version of the question is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Numbers rather than impressions, if you have them.

17 12CarlaRPh_TPA, steph_laguna, fiona_glasgow and 14 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
May 16, 2025 at 5:00 AM#2

Answering the narrow version, because the broad one does not have a single answer. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

16 11NauseaFreeNow, SteveThurs, B12Beth and 13 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
May 16, 2025 at 5:39 AM#3
Dr.NateNeph said:
The gap between trial results and real-world results is consistent and it is not fraud.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced heart failure hospitalization (HR 0.74) over 3 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
15 10LibrarianMeg, bri_stats, pete_manc_UK and 12 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
alex_tucson
Member
567
2,345
May 2024
Tucson, AZ
May 16, 2025 at 6:18 AM#4
Dr.BariatricHTX said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Same position here, arrived at the long way round. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

14 9ricardo_MIA, BrianDallas92, labquiet_amy and 11 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
May 16, 2025 at 9:56 AM#5

Adding the clinical framing, because it changes how the question reads.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

13 8B12Beth, RickReta_CO, PharmHunterJen and 10 others
Reply Quote Save Share Report

Similar Threads

BPC-157 oral vs injectable — bioavailability review and evidence15 replies
TB-500 for tissue repair — mechanism and clinical evidence4 replies
Selank and Semax — anxiolytic peptides overview2 replies
CJC-1295/Ipamorelin combination — GH secretagogue discussion23 replies
BPC-157 + GLP-1 stacking for gut healing — N=1 experience17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register